U.S. Researchers Begin Tests of New Anthrax Vaccine

U.S. researchers have begun a nationwide study to evaluate a new, experimental anthrax vaccine, the University of Rochester Medical Center announced yesterday (see GSN, April 28).

Researchers hope to enroll a total of 480 people at 11 sites by the end of next month to take part in the study, funded by the U.S. National Institute of Allergy and Infectious Diseases. Participants would be administered a new anthrax vaccine being developed by the U.S. company VaxGen that requires fewer injections than the current vaccine. The study also seeks to determine whether the new vaccine results in fewer side effects because it is based on technology that results in a more purified product (University of Rochester Medical Center release, April 28).

Back to top
About Newswire  |  Contact National Journal  |  Re-Use Guidelines © Copyright 2008 by National Journal Group, Inc. The material in this section is produced independently for NTI by National Journal Group, Inc. Any reproduction or retransmission, in whole or in part, is a violation of federal law and is strictly prohibited without the consent of the National Journal Group, Inc. All rights reserved.